Molnupiravir: First Approval

Molnupiravir (Lagevrio(R)) is an orally-administered antiviral prodrug that inhibits replication of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback Biotherapeutics for the prevention and treatment of Coronavirus disease 2019 (COVID-19). Molnupiravir received its first approval on 4 November 2021 in the UK for the treatment of mild to moderate COVID-19 in adults with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic test and who have at least one risk factor for developing severe illness. Molnupiravir is filed for approval and has emergency use authorization for the treatment of COVID-19 in several countries, including the USA, Japan and those in the EU. This article summarizes the milestones in the development of molnupiravir leading to this first approval for COVID-19.

Automated summary

Molnupiravir is an orally-administered antiviral drug that inhibits the replication of COVID-19 virus by inducing viral error. It has received approval in the UK for the treatment of mild to moderate COVID-19 and emergency use authorization in several countries.